Sexual Dysfunctions, Psychological Clinical Trial
Official title:
An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder
NCT number | NCT00746967 |
Other study ID # | A1481133 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | January 2003 |
Est. completion date | February 2004 |
Verified date | January 2021 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.
Status | Completed |
Enrollment | 267 |
Est. completion date | February 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Included were subjects who completed Pfizer study A1481082 or A1481123 without a major protocol violation and with all treatment-related adverse events resolved prior to crossover into the open-label study. - For subjects receiving hormone replacement therapy and/or selective serotonin reuptake inhibitor treatment, dosage of these must be stable at the start of this extension study and remain stable throughout. - Subjects should continue to maintain a stable sexual relationship throughout the study. Exclusion Criteria: - Excluded were subjects who experienced either treatment-related serious adverse events or significant treatment-related laboratory abnormalities in the previous study, and subjects who misused study medication and/or failed to adequately account for study medication in the previous study, or who were non-compliant with visits. - Also excluded were subjects who were currently prescribed and/or taking nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or aerosols). |
Country | Name | City | State |
---|---|---|---|
United States | Pfizer Investigational Site | Albany | California |
United States | Pfizer Investigational Site | Anchorage | Alaska |
United States | Pfizer Investigational Site | Anchorage | Alaska |
United States | Pfizer Investigational Site | Anderson | South Carolina |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Atlanta | Georgia |
United States | Pfizer Investigational Site | Aurora | Colorado |
United States | Pfizer Investigational Site | Austin | Texas |
United States | Pfizer Investigational Site | Austin | Texas |
United States | Pfizer Investigational Site | Aventura | Florida |
United States | Pfizer Investigational Site | Beachwood | Ohio |
United States | Pfizer Investigational Site | Berkeley | California |
United States | Pfizer Investigational Site | Beverly Hills | California |
United States | Pfizer Investigational Site | Beverly Hills | California |
United States | Pfizer Investigational Site | Boise | Idaho |
United States | Pfizer Investigational Site | Boise | Idaho |
United States | Pfizer Investigational Site | Brooksville | Florida |
United States | Pfizer Investigational Site | Burbank | California |
United States | Pfizer Investigational Site | Charlottesville | Virginia |
United States | Pfizer Investigational Site | Cheyenne | Wyoming |
United States | Pfizer Investigational Site | Cincinnati | Ohio |
United States | Pfizer Investigational Site | Crestview Hills | Kentucky |
United States | Pfizer Investigational Site | Creve Coeur | Missouri |
United States | Pfizer Investigational Site | Dallas | Texas |
United States | Pfizer Investigational Site | Evansville | Indiana |
United States | Pfizer Investigational Site | Fair Oaks | California |
United States | Pfizer Investigational Site | Florence | Kentucky |
United States | Pfizer Investigational Site | Fort Wayne | Indiana |
United States | Pfizer Investigational Site | Greenbelt | Maryland |
United States | Pfizer Investigational Site | Hamden | Connecticut |
United States | Pfizer Investigational Site | Henderson | Nevada |
United States | Pfizer Investigational Site | Hermosa Beach | California |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Huntsville | Alabama |
United States | Pfizer Investigational Site | Jensen Beach | Florida |
United States | Pfizer Investigational Site | Jonesboro | Arkansas |
United States | Pfizer Investigational Site | Kalamazoo | Michigan |
United States | Pfizer Investigational Site | Leawood | Kansas |
United States | Pfizer Investigational Site | Marietta | Georgia |
United States | Pfizer Investigational Site | Memphis | Tennessee |
United States | Pfizer Investigational Site | Metairie | Louisiana |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Milwaukee | Wisconsin |
United States | Pfizer Investigational Site | New Brunswick | New Jersey |
United States | Pfizer Investigational Site | New London | Connecticut |
United States | Pfizer Investigational Site | New Port Richey | Florida |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Newburgh | Indiana |
United States | Pfizer Investigational Site | North Las Vegas | Nevada |
United States | Pfizer Investigational Site | Oakland | California |
United States | Pfizer Investigational Site | Palm Harbor | Florida |
United States | Pfizer Investigational Site | Pembroke Pines | Florida |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Philadelphia | Pennsylvania |
United States | Pfizer Investigational Site | Plantation | Florida |
United States | Pfizer Investigational Site | Poughkeepsie | New York |
United States | Pfizer Investigational Site | Providence | Rhode Island |
United States | Pfizer Investigational Site | Reading | Pennsylvania |
United States | Pfizer Investigational Site | Reading | Pennsylvania |
United States | Pfizer Investigational Site | Renton | Washington |
United States | Pfizer Investigational Site | Richmond | Virginia |
United States | Pfizer Investigational Site | Rochester | New York |
United States | Pfizer Investigational Site | Saint Petersburg | Florida |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | Sandy | Utah |
United States | Pfizer Investigational Site | Santa Monica | California |
United States | Pfizer Investigational Site | Savannah | Georgia |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | Southfield | Michigan |
United States | Pfizer Investigational Site | Stuart | Florida |
United States | Pfizer Investigational Site | Stuart | Florida |
United States | Pfizer Investigational Site | Temple | Pennsylvania |
United States | Pfizer Investigational Site | Torrance | California |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Waterbury | Connecticut |
United States | Pfizer Investigational Site | West Palm Beach | Florida |
United States | Pfizer Investigational Site | West Reading | Pennsylvania |
United States | Pfizer Investigational Site | White Plains | New York |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety/toleration of oral sildenafil. | Continuous | ||
Secondary | The score for each of the individual questions 3,5 and 9 on the SQoL-F | Week 14 and Week 26 | ||
Secondary | The total satisfaction score on the Inventory of Treatment Satisfaction (ITS-modified EDITS) | Week 14 and Week 26 | ||
Secondary | The score for each of the individual questions 3,5,6 and 7 on the ITS-modified EDITS | Week 14 and Week 26 | ||
Secondary | The Arousal-lubrication Domain from the SFQ. The score for this domain is the sum of scores from Questions 11 and 12 from the SFQ | Week 14 and Week 26 | ||
Secondary | The Arousal-sensation Domain from the SFQ. The score for this domain is sum of scores from Questions 7,8,9 and 10 from the SFQ. | Week 14 and Week 26 | ||
Secondary | The total Quality of Life score on the Sexual Quality of Life (SQoL-F) | Week 14 and Week 26 | ||
Secondary | The Desire domain from the SFQ. Specifically, the sum of scores from questions 1,2,3,4,15 and 28 (frequency of pleasurable thoughts, wanted to be touched, wanted sex, initiated sex, had sex with penetration, looked forward to sex, respectively). | Week 14 and Week 26 | ||
Secondary | Question 16 from the SFQ at Weeks 14 and 26 (enjoyment of penetration and intercourse). | Week 14 and Week 26 | ||
Secondary | The Orgasm domain from the SFQ. The score for this domain is the sum of scores from questions 24,25 and 26 (orgasm frequency, level of pleasure and ease in achieving, respectively). | Week 14 and Week 26 | ||
Secondary | The individual questions of the Orgasm domain. | Week 14 and Week 26 | ||
Secondary | SFQ Question 27 (confidence as sexual partner). | Week 14 and Week 26 | ||
Secondary | SFQ Question 29 (disappointment with response). | Week 14 and Week 26 | ||
Secondary | Global Efficacy Question (SFQ Question 34, satisfaction with whole of sexual life) | Week 14 and Week 26 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00996164 -
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00996372 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
|
Phase 3 | |
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
Completed |
NCT00175539 -
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties
|
N/A | |
Completed |
NCT04792177 -
Internet-based Emotion Regulation Intervention for Sexual Health
|
N/A | |
Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
Completed |
NCT00491829 -
Flibanserin Versus Placebo in Premenopausal Women With HSDD
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Recruiting |
NCT05489133 -
Early Psychological Intervention After Rape
|
N/A | |
Completed |
NCT03775239 -
Mindfulness as Treatment of Sexological Problems
|
N/A | |
Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
Completed |
NCT01188603 -
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 1 | |
Completed |
NCT01771237 -
HIV Prevention Among Vulnerable Male Youth
|
N/A | |
Completed |
NCT00360529 -
24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360555 -
A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
Completed |
NCT00360243 -
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
|
Phase 3 | |
Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
Terminated |
NCT01057901 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
|
Phase 3 |